Evaluation of the DNA methylation in body fluids as biomarkers for the diagnosis and prognosis of metastases

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200060532

Enrollment

Unknown

Registered

2022-06-04

Start date

2022-06-19

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic cancers

Interventions

Gold Standard:Pathological diagnosis and/or clinical diagnosis

Index test:DNA methylation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Any male or female patient aged 18 or older; 2. Understand the purpose of the clinical trial and sign the informed consent; 3. Underwent pathological diagnosis of body fluids in this medical institution; 4. Sufficient remaining samples can be collected.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete personal information: name, age, pathology results, metastasis states, history of carcinoma; 2. Other conditions deemed inappropriate by the researcher.

Design outcomes

Primary

Measure	Time frame
DNA methylation;	—

Countries

China

Contacts

Public ContactYu Wenqiang

Institutes of Biomedical Sciences, Fudan University

yuwenqiang@epiprobe.com+86 15221889142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026